
Opinion|Videos|February 8, 2024
Overall Survival Update for KEYNOTE-564 in Renal Cell Carcinoma
Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5









































